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An improvedmultiplex PCR, using redesigned primers targeting the serovar 3 capsule locus, which differentiates serovars 3, 6,
and 8 Actinobacillus pleuropneumoniae isolates, is described. The new primers eliminate an aberrant serovar 3-indicative ampli-
con found in some serovar 6 clinical isolates. Furthermore, we have developed a newmultiplex PCR for the detection of serovars
1 to 3, 5 to 8, 10, and 12 along with apxIV, thus extending the utility of this diagnostic PCR to cover a broader range of isolates.
Actinobacillus pleuropneumoniae is a major cause of morbidityandmortality due to respiratory disease in pigs and is respon-
sible for substantial economic losses worldwide (1). There are 15
serovars of A. pleuropneumoniae (2), based on the presence of
surface carbohydrates, principally capsules, with their prevalence
varying between geographic regions. For example, serovars 1 and
5 are common in North and South America, and serovar 2 is
common in Europe (reviewed in reference 3; see references
therein), whereas these serovars are absent or rare in the United
Kingdom (4). Differences in virulence and immunogenicity have
been reported for different serovars (5), though within serovars,
isolates tend to be clonal (6, 7). Accurate serotyping is essential for
informed diagnosis, epidemiological investigation of outbreaks,
and detection of the emergence of serovars previously not found,
or rare, within a geographical region. The serovar of an isolate is
classically determined using antibody-based tests (3). However,
cross-reactivity is a major limitation and has been reported be-
tween serovars 1 and 9 (8), serovars 4 and 7 (9), and serovars 3, 6,
and 8 (reviewed in reference 10). Thus, multiplex PCRs based on
capsule loci have been developed, including those for serovars 2, 5,
and 6 (11), 1, 2, and 8 (12), and 1, 7, and 12 (13). We have addi-
tionally devised a multiplex PCR that determines whether an iso-
late is serovar 3, 6, or 8 (10). The latter multiplex PCR amplifies a
fragment of the A. pleuropneumoniae-specific apxIV gene and se-
rovar 3-, 6-, and 8-specific sequences derived from the capsule
loci. In recent years, we have observed in our collection (and oth-
ers have reported [14]) a double- banding pattern in some isolates,
so that it is not possible to distinguish between serovars 3 and 6. In
this study, we (i) discerned the genetic reason for the aberrant
serovar 3/6 double-banding pattern, (ii) developed a new serovar
3-6-8 PCR with modified serovar 3 primers that eliminate the
aberrant pattern, and (iii) extended that PCR to include a further
six serovars commonly found throughout theworld. This includes
the detection of serovar 10, for which a capsule locus-based PCR
has not been described previously.
MATERIALS AND METHODS
Bacterial strains. In this study, we used 15 referenceA. pleuropneumoniae
strains (see reference 10 for details), as well as a collection of 334A. pleuro-
pneumoniae clinical isolates from Denmark (n 166), the United King-
dom (n 154) (including 9 serovar 6 isolates that previously tested pos-
itive for serovars 3 and 6), Cyprus (n 6), Switzerland (n 6), andChina
(n  2). All the isolates were previously typed serologically and/or by
capsule-specific PCR. In addition, 31 strains of other porcine-associated
bacterial species were tested as negative controls These included Actino-
bacillus suis (n 5), Actinobacillus minor (n 3), Actinobacillus porciton-
sillarum (n 3), Actinobacillus porcinus (n 3), Actinobacillus indolicus
(n  3), Haemophilus parasuis (n  5), Pasteurella multocida (n  3),
Bordetella bronchiseptica (n  2), Mycoplasma hyopneumoniae (n  3),
and Streptococcus suis P1/7 (n 1).
Capsule regions ofMIDG2472 and 405. In this study, we have gener-
ated shotgun genome sequence data for the A. pleuropneumoniae serovar
6 United Kingdom clinical isolate MIDG2472, which shows the double-
banding pattern using the 3-6-8multiplex PCR previously described (10),
and for the serovar 8 reference strain, 405. A shotgun genome sequence
was generated from genomic DNA prepared using the Blood and Tissue
DNeasy kit (Qiagen) per the manufacturer’s instructions. Libraries were
prepared from 5 g genomic DNA by standard protocols (15, 16) and
paired-end sequencing was performed at the Wellcome Trust Sanger In-
stitute (Cambridge) on an Illumina HiSeq 2000 analyzer for 75 cycles.
Draft genome sequenceswere assembled usingVelvetOptimiser 2.2.0 (17)
and capsule loci were identified using BLAST searches (18). The complete
capsule loci for the other serovar strains (1, 2, 3, 5, 6, 10, and 12) were
identified from the available whole-genome sequences (19–21).
MultiplexPCRs.Theprimers used in this study are detailed inTable 1.
The binding sites for the serovar 3, 6, and 8 primers in the respective
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capsule loci are shown in Fig. 1.Our originalmultiplex PCR for serovars 3,
6, and 8 was carried out as previously described (10). For the new multi-
plex PCR, the Qiagen Multiplex PCR Plus kit was used according to the
manufacturer’s instructions (Qiagen). Each reaction mixture contained
25 l multiplex PCR master, 5 l CoralLoad dye, 5 l genomic DNA, 10
pairs of primers (each 10 pmol), and 13l water to a final volume of 50l.
Genomic DNA extracted using the DNeasy blood and tissue kit (Qiagen)
or present in boiled bacterial lysates prepared as described by Jessing et al.
(11) was used as the DNA template for PCR amplification. Targeted gene
amplification was initiated at 95°C for 5 min to activate the HotStar Taq
plus DNA polymerase, followed by 25 cycles of 3-step cycling of denatur-
ation at 95°C for 30 s, annealing at 61°C for 90 s, extension at 72°C for 2
min, and a final extension at 68°C for 15 min. PCR products were sepa-
rated by 1.5% agarose gel electrophoresis, stainedwith ethidiumbromide,
and analyzed using a Gel Doc EI imager (Bio-Rad).
Nucleotide sequence accessionnumbers.TheDNA sequences of the
capsule loci of strains MIDG2472 and 405 have been deposited in
GenBank under accession numbers KJ685492 and KJ685493, respec-
tively.
RESULTS AND DISCUSSION
The first aim of this study was to determine the reason for the
amplification of bands indicating serovars 3 and 6 in some serovar
6 clinical isolates. In our original multiplex PCR, the serovar
6-specific primers (AP6F and AP6R) were derived from a previ-
ously published PCR (11, 12). Their binding sites in the serovar 6
capsular locus are shown in Fig. 1. The serovar 3 primers (AP3NF
and AP3NR) were designed to amplify a 921-bp fragment from
cps3A (APJL_1614) to cpxD (APJL_1615), and the serovar 8 prim-
ers (AP8NF and AP8NR) were designed to amplify a 1,106-bp
fragment from cps8A to cps8B, as indicated in Fig. 1 for the serovar
3 and serovar 8 capsule loci. Our original serovar 3 primers
(AP3NF and AP3NR) were based on a DNA sequence that we
obtained from a chromosome-walking strategy using serovar 3
reference strain S1421 prior to the availability of the serovar 3
JL03 whole-genome sequence (10, 22). AP3NF and AP3NR
amplify a 921-bp PCR product in S1421 (serovar 3) but not the
serovar 6 Femo reference strain (Fig. 2A, lanes 1 and 2),
whereas MIDG2472 amplifies this 921-bp band as well as the
serovar 6-indicative 718-bp product (Fig. 2A, lane 3). DNA
sequence analysis of the capsule locus of MIDG2472 and Femo
provides an explanation for the aberrant double-banding pat-
tern. In MIDG2472, in addition to the serovar 6-specific region
amplified by AP6F and AP6R, there are perfect binding sites for
AP3NF and AP3NR (Fig. 1 and 3). In Femo, there is a binding
site for AP3NR, but that for AP3NF is partially redundant (Fig.
3), such that, under the PCR conditions used, no amplification
occurs. In strain 405 (serovar 8), the AP3NR binding sequence
is partially redundant (Fig. 3), such that amplification with
AP3NF does not occur. Thus, in Femo, only a 718-bp serovar
6-specific amplicon is present, while in MIDG2472 there is an
additional 921-bp amplicon resulting from binding of the se-
rovar 3 primer pair. In summary, the aberrant serovar 3/6
banding pattern results from the lack of specificity of the sero-
var 3 primers AP3NF and AP3NR in some serovar 6 isolates,
such as MIDG2472. The two Japanese isolates with aberrant
banding patterns were also found to have perfect priming sites
for AP3NF and AP3NR (14). Thus, to eliminate the aberrant
3/6 banding pattern, we have reformulated our original 3-6-8
PCR by replacement of the serovar 3 primers. All other primers
TABLE 1 Primers used in this study
Primer name Sequence Target genea
Amplicon
size (bp)
Reference or
source
AP1F CTGGAGTAATTACGGCGACTATTCC cps1B 959 This study
AP1R AGGAGAAGCTAGTAGTACTTGCATTTTC cps1B
AP2F GAGTGTGATGATGATGCTCTGGTTC hypb 247 This study
AP2R TACCAATAACTGTTGCAACTAACGC hypb
AP3DF CTATCATCTGTGCCAAGCTTACTACAC cps9D= 520 This study
AP3DR GGTTTAGAGGGGCAAATTGACTTG cps9D=
AP3NF TTTGCGCTGTAGTGCTCCAAT cpxD 921 10; not part of the
9-serovar PCRAP3NR AACAAATAAAGTTGCTCGAAAGTA cps2A
AP5F AGCCACAAGACCCGAATGGTATAATG cps5B 825 This study
AP5R CCATCAAATGCAGCTTCAAGGAGC cps5B
AP6NF AACCACTCACTTTCCACATTA cps6D 718 10
AP6NR AATCGGAAGGTTTTGGTCTCGTG cps6E
AP7F TCTAGGTATTACTGGTGTTCCTGATG cps2D 600 This study
AP7R CGTCCAACACGAGCAACTACG cps2D
AP8NF TTAGTTGCGCAAACGGCTTTTGAA cps8A 1,106 10
AP8NR GATTAAACTGGTCCGTCGAAATG cps8B
AP10F GGTGGTGATGGAACAAGGTTATGG cps10A 183 This study
AP10R CTGTAATTGATGCGAAATAGTAGATTGGTGC cps10A
AP12F TAAAGGTATTATAACGCCGGCTCT cps1A 347 This study
AP12R CTCCCATCTGTTGTCTAAGTAGTAG cps1A
apxIVA1 TTATCCGAACTTTGGTTTAGCC apxIV 418 10
apxIVA3 CATATTTGATAAAACCATCCGTC Intergenicc
oAPXIVA-TSP1 CTTTCGCTCATGCGACTATG apxIV 423 23; not part of the
9-serovar PCRoAPXIVA-TSP2 TTTCCGTCCGGTTTATTCAG apxIV
a Capsule gene designations are those used by Xu et al. (20). There are some conserved gene names between different serovars with similar capsule types. However, primers were
designed to bind strictly serovar-specific sequences within these genes.
b Serovar 2-specific open reading frame (ORF) immediately downstream of cpsD encoding a hypothetical protein.
c Intergenic region immediately downstream of apxIV.
A. pleuropneumoniae 9-Serovar Multiplex PCR
July 2014 Volume 52 Number 7 jcm.asm.org 2381
and PCR conditions were otherwise as described originally
(10). The new serovar 3 PCR primers AP3DF and AP3DR are
designed to amplify a 520-bp fragment of the serovar 3-specific
APJL_1611 (cpsD) gene (Fig. 1). A comparison of old and new
PCRs with the serovar 3, 6, and 8 reference strains and serovar
6 “aberrant” strain (MIDG2472) is shown in Fig. 2. The new
PCR (Fig. 2B) eliminates the aberrant banding, there being
amplicons at 520 bp, 718 bp, and 1,106 bp specific for serovar 3,
6, and 8 strains/isolates, respectively. For the unequivocal dif-
ferentiation of serovar 3, 6, and 8 A. pleuropneumoniae isolates,
we recommend that investigators use themodified PCR described
in this study.
Next,theutilityofthenewserovar3-6-8PCRwasextendedtoinclude
serovars1,2,5,7,10,and12,whicharemoreprevalentinsomecountries,
but which are either absent (as is the case for serovars 1 and 5) or are
comparatively rare in the United Kingdom. Serovar-specific sequences
were derived fromwhole-genome sequences:GenBank accessionnum-
bers ADOD00000000 (4074, serovar 1), ADOE00000000 (S1536, sero-
var 2), CP000687 (JL03, serovar 3), ADOF00000000 (M62 serovar 4),
CP000569 (L20, serovar 5), ADOG00000000 (Femo, serovar 6),
FIG 1 Location of primers within capsule loci of A. pleuropneumoniae serovar (Sero) 3, 6, and 8 strains. See Table 1 for oligonucleotide sequences of primers.
FIG 2 Comparison of original (10) and new (this study) multiplex PCRs for detection of A. pleuropneumoniae serovars 3, 6, and 8. (A) Original multiplex PCR
for amplification of apxIV (418 bp), serotype 3 (921 bp), serotype 6 (718 bp), and serotype 8 (1,106 bp) amplicons. (B) Newmultiplex PCR for amplification of
apxIV (418 bp), serotype 3 (520 bp), serotype 6 (718 bp), and serotype 8 (1,106 bp) amplicons. LaneM, 100-bp ladder; lanes 1, serovar 3, S1421; lanes 2, serovar
6, Femo; lanes 3, serovar 6, MIDG2472; lanes 4, serovar 8, 405.
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CP001091 (AP76, serovar 7), ADOI00000000 (CVJ13261, serovar 9),
ADOJ00000000 (D13039, serovar 10),ADOK00000000 (56153, serovar
11), ADOL00000000 (1096, serovar 12), and ADOM00000000 (N273,
serovar13).Thedetailsoftheprimerpairsthatwerederivedforuseinthe
9-serovar multiplex PCR are provided in Table 1. The 9-serovar multi-
plex PCR was initially tested against the A. pleuropneumoniae refer-
ence strains (Fig. 4). As expected, all of the reference strains had an
apxIV amplicon of 418 bp, as reported previously (10), and ap-
propriate serotype-specific amplicons of predicted sizes were de-
tected for the reference strains of serovars 1 to 3, 5 to 8, 10, and 12.
Subsequently, the PCRwas evaluated using clinicalA. pleuropneu-
moniae isolates, as well as other actinobacilli, other Pasteurel-
laceae, and other major pathogens of pigs. Additionally, virtual
PCRs were carried out on available genomes of the species inves-
tigated, where available. A breakdown of the PCR results for clin-
ical A. pleuropneumoniae isolates is shown in Table 2. Serovar
designation of isolates had been carried out either by PCR, as
described previously, or by antibody-based serotyping. All of the
334 clinical A. pleuropneumoniae strains tested amplified the pre-
dicted serovar amplicons. Five strains were positive for the serovar
1 amplicon but did not amplify the 418-bp apxIV band. These
strains were subsequently tested for apxIV using the primers
oAPXIVA-TSP1 and oAPXIVA-TSP2 (23), and each strain pro-
duced a 423-bp band indicating that apxIV is present (with no
ISApl1 insertion).We recommend thatwhere an isolate is strongly
suspected to be A. pleuropneumoniae and there is a lack of either
apxIV or a serovar-specific amplicon in our 9-serovar PCR, re-
searchers retest the isolate with alternate A. pleuropneumoniae-
specific primers such as those indicated above. If the isolate is
confirmed asA. pleuropneumoniae, it is likely that its serovar is not
covered by our multiplex PCR. While other multiplex PCRs have
been reported for all but serovar 10, these have typically involved
coverage of three serovars (see references 11–13). None have been
described that include serovar 10 as described here. Serovar 10
isolates have been reported in Canada, Denmark, Germany, Hun-
gary, Spain (3), and the United Kingdom (4), although not as one
of the prevalent serovars.
The specificity of themultiplex PCRwas further tested using 31
isolates representing porcine-associated bacterial species other
than A. pleuropneumoniae, which were derived from our collec-
tion and have been assigned at the species level by conventional
biochemical testing. None of these strains produced any ampli-
cons with the new 9-serovar multiplex PCR.
In summary, we have developed a single-tube multiplex PCR
that unequivocally differentiates A. pleuropneumoniae serovars 1
to 3, 5 to 8, 10, and 12. With the use of our well-characterized
collection of A. pleuropneumoniae isolates and other porcine-as-
sociated bacterial species, the new PCR was 100% sensitive and
specific for serotyping. In regard to the United Kingdom, the PCR
covers all of the serovars (2, 3, 6, 7, 8, 10, and 12) that were previ-
FIG 3 Alignment of the binding sites for primers AP3NF and AP3NRwithin the capsule loci of A. pleuropneumoniae serovar (Sero) 3, 6, and 8 strains. There are
perfect binding sites for the AP3NF primer in the cpxD gene in strains JL03, MIDG2472, and 405. In strain Femo, the cpxD sequence differs slightly at the target
site, such that the primer AP3NF does not bind. There are perfect binding sites for AP3NR in the cpsA gene in strains JL03, Femo, andMIDG2472. In strain 405,
the cpsA sequence differs slightly at the target site, such that the primer AP3NR does not bind.
FIG4 Multiplex PCR for detection ofA. pleuropneumoniae serovars 1 to 3, 5 to 8, 10, and 12 and apxIV. An apxIV (418 bp) amplicon is detected in all 15 serovars,
while serovar-specific amplicons are detected for serovar 1 (959 bp), serovar 2 (247 bp), serovar 3 (520 bp), serovar 5 (825 bp), serovar 6 (718 bp), serovar 7 (600
bp), serovar 8 (1,106 bp), serovar 10 (183 bp), and serovar 12 (347 bp). Lane M, 100-bp ladder; lane 1, 4074T; lane 2, S1536; lane 3, S1421; lane 4, M62; lane 5,
L20; lane 6, Femo; lane 7, WF83; lane 8, 405; lane 9, CVJ13261; lane 10, D13039; lane 11, 56153; lane 12, 8329; lane 13, N-273; lane 14, 3906; lane 15, HS143.
A. pleuropneumoniae 9-Serovar Multiplex PCR
July 2014 Volume 52 Number 7 jcm.asm.org 2383
ously reported (4), although a single serovar 9 isolate has subse-
quently be found (24).
The inclusion of apxIV-specific primers should allow for de-
tection of A. pleuropneumoniae serovars not included in the mul-
tiplex PCR, though we have identified a small number (5/334) of
strains that failed to produce the predicted 418-bp amplicon. In
those strains, an apxIV band was obtained with alternate primers.
Although we did not investigate further, the new multiplex PCR
could be adapted to detect relevant serotypes found in different
countries by excluding or including capsule-specific primers for
other serovars as required.
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